Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Docosanol Cream, 10% (OTC) has an estimated market size of US$60 million for twelve months ending December 2021 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
